Active substance
Results for the substance vorapaxar
1 result
About this active substance
Vorapaxar is an antiplatelet medication used to reduce the risk of cardiovascular events such as myocardial infarction and stroke in patients with a history of coronary artery disease or peripheral arterial disease. It acts as a protease-activated receptor-1 (PAR-1) antagonist, inhibiting platelet activation by thrombin, thereby reducing blood clot formation.
Vorapaxar is administered orally, usually once daily, in combination with other antiplatelet medications such as aspirin or clopidogrel. The treatment is intended for long-term use but is not recommended for patients with a history of hemorrhagic stroke or other conditions that increase the risk of bleeding.
Common side effects include bleeding, anemia, hematomas, and nausea. In rare cases, severe bleeding events such as intracranial or gastrointestinal hemorrhage may occur.
Patients taking vorapaxar should be regularly monitored for signs of bleeding and treatment efficacy. The medication is an effective option for preventing thrombotic events in patients at high cardiovascular risk.
Vorapaxar is administered orally, usually once daily, in combination with other antiplatelet medications such as aspirin or clopidogrel. The treatment is intended for long-term use but is not recommended for patients with a history of hemorrhagic stroke or other conditions that increase the risk of bleeding.
Common side effects include bleeding, anemia, hematomas, and nausea. In rare cases, severe bleeding events such as intracranial or gastrointestinal hemorrhage may occur.
Patients taking vorapaxar should be regularly monitored for signs of bleeding and treatment efficacy. The medication is an effective option for preventing thrombotic events in patients at high cardiovascular risk.